Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes Sells 1,000 Shares of Stock

Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes sold 1,000 shares of Cardlytics stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $90.00, for a total transaction of $90,000.00. Following the completion of the sale, the chief executive officer now owns 386,403 shares in the company, valued at approximately $34,776,270. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Scott D. Grimes also recently made the following trade(s):

  • On Wednesday, January 8th, Scott D. Grimes sold 1,000 shares of Cardlytics stock. The shares were sold at an average price of $66.61, for a total transaction of $66,610.00.

NASDAQ:CDLX opened at $83.88 on Thursday. The company’s 50-day moving average price is $87.66 and its 200-day moving average price is $55.65. Cardlytics Inc has a twelve month low of $14.14 and a twelve month high of $107.50.

Several large investors have recently bought and sold shares of CDLX. Great West Life Assurance Co. Can purchased a new position in shares of Cardlytics in the fourth quarter worth about $83,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Cardlytics in the fourth quarter worth about $88,000. SG Americas Securities LLC purchased a new position in shares of Cardlytics in the fourth quarter worth about $110,000. Tower Research Capital LLC TRC lifted its stake in shares of Cardlytics by 35.0% in the third quarter. Tower Research Capital LLC TRC now owns 4,079 shares of the company’s stock worth $137,000 after buying an additional 1,057 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY purchased a new position in shares of Cardlytics in the third quarter worth about $161,000.

Several analysts have recently issued reports on CDLX shares. Bank of America reiterated an “average” rating and issued a $100.00 target price on shares of Cardlytics in a research report on Tuesday, January 14th. Craig Hallum raised their price target on shares of Cardlytics from $75.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th. Zacks Investment Research raised shares of Cardlytics from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a research note on Thursday, January 16th. BidaskClub downgraded shares of Cardlytics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 22nd. Finally, Raymond James downgraded shares of Cardlytics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 15th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. Cardlytics has a consensus rating of “Buy” and an average price target of $66.43.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: What is a back-end load?

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.